Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema

Reuters

Mar 20

Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema

Pharvaris reported that two articles in The Lancet Haematology published results from the randomized Phase 2 CHAPTER-1 and RAPIDe-1 studies of deucrictibant, an oral bradykinin B2 receptor antagonist being developed for hereditary angioedema.
CHAPTER-1 evaluated prophylaxis and showed a statistically significant reduction in attack occurrence versus placebo, with deucrictibant reported as well tolerated at both doses tested.
RAPIDe-1 evaluated on-demand treatment and showed statistically significant reductions in attack severity versus placebo and reduced time to symptom relief and resolution, with deucrictibant reported as well tolerated at all doses tested.
Topline data from the Phase 3 CHAPTER-3 prophylaxis study are expected in Q3 2026.
Confirmatory Phase 3 RAPIDe-3 on-demand data were already presented at the American Academy of Allergy, Asthma & Immunology 2026 Annual Meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief on March 20, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2620870037"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620870037\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620870037?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 18:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620870037","market":"fut","top_or_hot":-1,"title":"Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Pharvaris reported that two articles in The Lancet Haematology published results from the randomized Phase 2 CHAPTER-1 and RAPIDe-1 studies of deucrictibant, an oral bradykinin B2 receptor antagonist being developed for hereditary angioedema.\n        </li>\n<li>\n          CHAPTER-1 evaluated prophylaxis and showed a statistically significant reduction in attack occurrence versus placebo, with deucrictibant reported as well tolerated at both doses tested.\n        </li>\n<li>\n          RAPIDe-1 evaluated on-demand treatment and showed statistically significant reductions in attack severity versus placebo and reduced time to symptom relief and resolution, with deucrictibant reported as well tolerated at all doses tested.\n        </li>\n<li>\n          Topline data from the Phase 3 CHAPTER-3 prophylaxis study are expected in Q3 2026.\n        </li>\n<li>\n          Confirmatory Phase 3 RAPIDe-3 on-demand data were already presented at the American Academy of Allergy, Asthma &amp; Immunology 2026 Annual Meeting.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief on March 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-20 18:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Pharvaris reported that two articles in The Lancet Haematology published results from the randomized Phase 2 CHAPTER-1 and RAPIDe-1 studies of deucrictibant, an oral bradykinin B2 receptor antagonist being developed for hereditary angioedema.\n        </li>\n<li>\n          CHAPTER-1 evaluated prophylaxis and showed a statistically significant reduction in attack occurrence versus placebo, with deucrictibant reported as well tolerated at both doses tested.\n        </li>\n<li>\n          RAPIDe-1 evaluated on-demand treatment and showed statistically significant reductions in attack severity versus placebo and reduced time to symptom relief and resolution, with deucrictibant reported as well tolerated at all doses tested.\n        </li>\n<li>\n          Topline data from the Phase 3 CHAPTER-3 prophylaxis study are expected in Q3 2026.\n        </li>\n<li>\n          Confirmatory Phase 3 RAPIDe-3 on-demand data were already presented at the American Academy of Allergy, Asthma &amp; Immunology 2026 Annual Meeting.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief on March 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL78GY3F:1","article_id":"2620870037","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620870037","pubTimestamp":1774004038,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pharvaris reported that two articles in The Lancet Haematology published results from the randomized Phase 2 CHAPTER-1 and RAPIDe-1 studies of deucrictibant, an oral bradykinin B2 receptor antagonist being developed for hereditary angioedema.CHAPTER-1 evaluated prophylaxis and showed a statistically significant reduction in attack occurrence versus placebo, with deucrictibant reported as well tolerated at both doses tested.RAPIDe-1 evaluated on-demand treatment and showed statistically significant reductions in attack severity versus placebo and reduced time to symptom relief and resolution, with deucrictibant reported as well tolerated at all doses tested.Topline data from the Phase 3 CHAPTER-3 prophylaxis study are expected in Q3 2026.Confirmatory Phase 3 RAPIDe-3 on-demand data were already presented at the American Academy of Allergy, Asthma & Immunology 2026 Annual Meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Whi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PHVS":"Pharvaris N.V."},"translate_title":"Pharvaris报告口服deucrictibant治疗遗传性血管性水肿的2期CHAPTER-1和RAPIDe-1试验结果","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHVS":0.9},"content_text":"Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema\n    \n\n\n          Pharvaris reported that two articles in The Lancet Haematology published results from the randomized Phase 2 CHAPTER-1 and RAPIDe-1 studies of deucrictibant, an oral bradykinin B2 receptor antagonist being developed for hereditary angioedema.\n        \n\n          CHAPTER-1 evaluated prophylaxis and showed a statistically significant reduction in attack occurrence versus placebo, with deucrictibant reported as well tolerated at both doses tested.\n        \n\n          RAPIDe-1 evaluated on-demand treatment and showed statistically significant reductions in attack severity versus placebo and reduced time to symptom relief and resolution, with deucrictibant reported as well tolerated at all doses tested.\n        \n\n          Topline data from the Phase 3 CHAPTER-3 prophylaxis study are expected in Q3 2026.\n        \n\n          Confirmatory Phase 3 RAPIDe-3 on-demand data were already presented at the American Academy of Allergy, Asthma & Immunology 2026 Annual Meeting.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief on March 20, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}